Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Alnylam Pharmaceuticals stock in Canada | $141.99
Own Alnylam Pharmaceuticals shares in just a few minutes.
Alnylam Pharmaceuticals is a biotechnology business based in the US. Alnylam Pharmaceuticals stocks (ALNY.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $166.5 – an increase of 1.86% over the previous week. Alnylam Pharmaceuticals employs 1,453 staff and has a trailing 12-month revenue of around $570.9 million.
How to buy Alnylam Pharmaceuticals stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: ALNY in this case.
- Research Alnylam Pharmaceuticals stocks. The platform should provide the latest information available.
- Buy your Alnylam Pharmaceuticals stocks. It's that simple.
What's in this guide?
- Can I buy shares in Alnylam Pharmaceuticals?
- Has coronavirus impacted Alnylam Pharmaceuticals shares?
- Alnylam Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Alnylam Pharmaceuticals stock a buy or sell?
- Alnylam Pharmaceuticals performance over time
- Can I short Alnylam Pharmaceuticals shares?
- Alnylam Pharmaceuticals's financials
- How volatile are Alnylam Pharmaceuticals shares?
- Does Alnylam Pharmaceuticals pay a dividend?
- Other common questions
How has Coronavirus impacted Alnylam Pharmaceuticals's stock price?
Since the stock market crash in March caused by coronavirus, Alnylam Pharmaceuticals's stock price has had significant positive movement.
Its last market close was $141.99, which is 7.72% up on its pre-crash value of $131.03 and 67.11% up on the lowest point reached during the March crash when the stocks fell as low as $84.97.
If you had bought $1,000 worth of Alnylam Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $863.80 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,238.15.
Alnylam Pharmaceuticals stock priceUse our graph to track the performance of ALNY stocks over time.
Alnylam Pharmaceuticals stocks at a glance
|Latest market close||$141.99|
|52-week range||$119.29 - $184.45|
|50-day moving average||$173.4662|
|200-day moving average||$152.8093|
|Wall St. target price||$174.78|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-8.254|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Alnylam Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Alnylam Pharmaceuticals price performance over time
|1 month (2021-07-02)||-17.17%|
|3 months (2021-04-30)||0.96%|
Alnylam Pharmaceuticals financials
|Revenue TTM||USD$570.9 million|
|Gross profit TTM||USD$414.8 million|
|Return on assets TTM||-18.17%|
|Return on equity TTM||-77.01%|
|Market capitalisation||USD$21.4 billion|
TTM: trailing 12 months
How to short and sell Alnylam Pharmaceuticals stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "ALNY.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 4.2 million Alnylam Pharmaceuticals stocks held short by investors – that's known as Alnylam Pharmaceuticals's "short interest". This figure is 2.4% down from 4.3 million last month.
There are a few different ways that this level of interest in shorting Alnylam Pharmaceuticals stocks can be evaluated.
Alnylam Pharmaceuticals's "short interest ratio" (SIR)
Alnylam Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alnylam Pharmaceuticals stocks currently shorted divided by the average quantity of Alnylam Pharmaceuticals stocks traded daily (recently around 757982.58527828). Alnylam Pharmaceuticals's SIR currently stands at 5.57. In other words for every 100,000 Alnylam Pharmaceuticals stocks traded daily on the market, roughly 5570 stocks are currently held short.
However Alnylam Pharmaceuticals's short interest can also be evaluated against the total number of Alnylam Pharmaceuticals stocks, or, against the total number of tradable Alnylam Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alnylam Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding stocks (for every 100,000 Alnylam Pharmaceuticals stocks in existence, roughly 40 stocks are currently held short) or 0.0361% of the tradable stocks (for every 100,000 tradable Alnylam Pharmaceuticals stocks, roughly 36 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Alnylam Pharmaceuticals.
Find out more about how you can short Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals stock dividends
We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Alnylam Pharmaceuticals stock price volatility
Over the last 12 months, Alnylam Pharmaceuticals's stocks have ranged in value from as little as $119.29 up to $184.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 1.228. This would suggest that Alnylam Pharmaceuticals's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Alnylam Pharmaceuticals overview
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Stocks similar to Alnylam Pharmaceuticals
Alnylam Pharmaceuticals in the news
Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More
PeptiDream Inks $2.2B Deal To Broaden Alnylam's siRNA Delivery Scope
PeptiDream Inks $2.2B Deal To Broaden Alnylam's siRNA Delivery Scope
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to invest $1 million
Here are the top 5 ways you should invest $1 million.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada when it goes public
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.